Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Freedom Investment Management Inc.

Freedom Investment Management Inc. reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 934 shares of the biopharmaceutical company’s stock after selling 94 shares during the quarter. Freedom Investment Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $305,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ALNY. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. GAMMA Investing LLC grew its position in shares of Alnylam Pharmaceuticals by 14.3% during the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 77 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 3.0% during the first quarter. Sequoia Financial Advisors LLC now owns 3,395 shares of the biopharmaceutical company’s stock worth $917,000 after buying an additional 99 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $69,292,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. The trade was a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the completion of the sale, the executive vice president owned 25,231 shares of the company’s stock, valued at approximately $11,405,673.55. This represents a 8.82% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock valued at $44,160,261 in the last 90 days. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $463.43 on Monday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The stock has a 50 day moving average of $459.27 and a two-hundred day moving average of $361.80. The stock has a market cap of $60.75 billion, a P/E ratio of -187.62 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ALNY. The Goldman Sachs Group boosted their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Royal Bank Of Canada boosted their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. UBS Group upped their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Wolfe Research raised Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $466.92.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.